Quanterix (QTRX) to Release Quarterly Earnings on Thursday

Quanterix (NASDAQ:QTRX) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $37.4620 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.12. The business had revenue of $35.90 million for the quarter, compared to analysts’ expectations of $36.84 million. Quanterix had a negative net margin of 71.86% and a negative return on equity of 23.92%.

Quanterix Stock Down 0.7%

Shares of QTRX stock traded down $0.03 during trading hours on Tuesday, reaching $3.68. The company’s stock had a trading volume of 69,916 shares, compared to its average volume of 911,972. The firm’s 50 day simple moving average is $3.63 and its 200-day simple moving average is $4.31. The company has a market capitalization of $173.51 million, a price-to-earnings ratio of -1.57 and a beta of 1.07. Quanterix has a fifty-two week low of $2.39 and a fifty-two week high of $8.77.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Weiss Ratings downgraded Quanterix from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Canaccord Genuity Group decreased their target price on Quanterix from $8.00 to $4.00 and set a “hold” rating on the stock in a research report on Monday, April 20th. TD Cowen lowered their target price on Quanterix from $7.00 to $4.00 and set a “hold” rating for the company in a research note on Thursday, May 7th. Finally, Wall Street Zen raised shares of Quanterix from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Quanterix has a consensus rating of “Reduce” and an average price target of $4.00.

Institutional Trading of Quanterix

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Quadrature Capital Ltd bought a new stake in Quanterix during the 4th quarter worth approximately $138,000. ExodusPoint Capital Management LP bought a new position in shares of Quanterix during the fourth quarter valued at $153,000. LPL Financial LLC acquired a new position in shares of Quanterix during the fourth quarter worth $158,000. Brevan Howard Capital Management LP grew its stake in shares of Quanterix by 60.2% in the third quarter. Brevan Howard Capital Management LP now owns 23,244 shares of the company’s stock worth $126,000 after purchasing an additional 8,739 shares during the last quarter. Finally, Intech Investment Management LLC grew its stake in shares of Quanterix by 13.4% in the third quarter. Intech Investment Management LLC now owns 19,161 shares of the company’s stock worth $104,000 after purchasing an additional 2,268 shares during the last quarter. 86.48% of the stock is currently owned by institutional investors.

About Quanterix

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.